Volume | 13,750,931 |
|
|||||
News | - | ||||||
Day High | 0.4879 | Low High |
|||||
Day Low | 0.36 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sonnet BioTherapeutics Holdings Inc | SONN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.43 | 0.36 | 0.4879 | 0.4299 | 0.40 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
17,487 | 13,750,931 | $ 0.435473 | $ 5,988,159 | - | 0.205 - 4.5626 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:51 | formt | 200 | $ 0.429 | USD |
Sonnet BioTherapeutics Holdings Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 8.68M | 20.23M | 18.53M | $ 36.45k | $ -56.67k | -0.34 | -153.16 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 58.04k | 1.40% |
Sonnet BioTherapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SONN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.2792 | 0.4879 | 0.2388 | 0.3821607 | 12,351,786 | 0.1498 | 53.65% |
1 Month | 0.2352 | 0.4879 | 0.205 | 0.3403062 | 4,832,868 | 0.1938 | 82.4% |
3 Months | 0.83 | 0.8499 | 0.205 | 0.3290213 | 2,553,037 | -0.401 | -48.31% |
6 Months | 0.97 | 1.68 | 0.205 | 0.4889069 | 1,452,374 | -0.541 | -55.77% |
1 Year | 3.7128 | 4.5626 | 0.205 | 2.11 | 2,628,056 | -3.28 | -88.45% |
3 Years | 60.20 | 110.46 | 0.205 | 14.66 | 3,161,496 | -59.77 | -99.29% |
5 Years | 87.08 | 226.80 | 0.205 | 16.28 | 3,082,065 | -86.65 | -99.51% |
Sonnet BioTherapeutics Description
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |